Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma

LESSONS LEARNED: Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has no single‐agent antitumor activity. Enzalutamide,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Harding, James J., Kelley, Robin K., Tan, Benjamin, Capanu, Marinela, Do, Gian Kinh, Shia, Jinru, Chou, Joanne F., Ferrer, Christine S., Boussayoud, Chayma, Muenkel, Kerri, Yarmohammadi, Hooman, El Dika, Imane, Khalil, Danny N., Ruiz, Carmen, Rodriguez‐Lee, Mariam, Kuhn, Peter, Wilton, John, Iyer, Renuka, Abou‐Alfa, Ghassan K.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186405/
https://ncbi.nlm.nih.gov/pubmed/32548867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0521
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados